Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P110012/S022

Vysis ALK Break Apart FISH Probe Kit

Abbott Molecular, Inc. · Decision date Aug 5, 2025

FDA DECISIONP110012/S022

What did the FDA approve?

FDA records P110012/S022 as a supplement to PMA P110012, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Aug 5, 2025.

FDA approval order statement

Approval of the expansion of the Indications for Use for the Vysis ALK Break Apart FISH Probe Kit to include an indication for ENSACOVE (ensartinib). The device, as modified, will be marketed under the trade name Vysis ALK Break Apart FISH Probe Kit and is indicated for:INTENDED USE The Vysis ALK Break Apart FISH Probe Kit is a qualitative test to detect rearrangements involving the ALK gene via fluorescence in situ hybridization (FISH) in formalin-fixed paraffin-embedded (FFPE) tissue specimens from non-small cell lung cancer (NSCLC) patients.INDICATION FOR USE The Vysis ALK Break Apart FISH Probe Kit is indicated as an aid in identifying patients eligible for treatment with XALKORI (crizotinib), ALUNBRIG (brigatinib), and ENSACOVE (ensartinib) in accordance with the approved therapeutic product labeling.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Pathology
Decision date
Aug 5, 2025
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P110012/S022
Regulatory pathway
PMA supplement
Product code
OWE
Decision code
APPR
Decision date
Aug 5, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Fluorescence In Situ Hybridization, Anaplastic Lymphoma Kinase, Gene Rearrangement.

Product code
OWE
FDA device class
2

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P110012/S022 received

    Application receipt date recorded by FDA.

  2. P110012/S022 · FDA decision

    Normal 180 Day Track

  3. P110012/S023 · Related supplement

    Vysis ALK Break Apart FISH Probe Kit

Timeline entries are records held by MedtechLedger for P110012. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P110012

Product / regulatory recordCompanyPathwayDecision dateSource
Abbott Molecular, Inc.PMA supplementFeb 18, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Molecular, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1300 E Touhy Ave., Des Plaines, IL, 60018

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records